These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20346655)

  • 21. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of a series of hydroxybenzylphenylamine derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity.
    Chen H; Bashiardes G; Mailliet P; Commercon A; Sounigo F; Boiziau J; Parker F; Tocque B; Roques BP; Garbay C
    Anticancer Drug Des; 1996 Jan; 11(1):49-71. PubMed ID: 8639248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
    Kitano Y; Suzuki T; Kawahara E; Yamazaki T
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
    Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design strategies for protein kinase inhibitors.
    Parang K; Sun G
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):617-29. PubMed ID: 15503864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
    Cao H; Zhang H; Zheng X; Gao D
    J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
    Ducray R; Simpson I; Jung FH; Nissink JW; Kenny PW; Fitzek M; Walker GE; Ward LT; Hudson K
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4698-701. PubMed ID: 21775140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.
    Rode HB; Sos ML; Grütter C; Heynck S; Simard JR; Rauh D
    Bioorg Med Chem; 2011 Jan; 19(1):429-39. PubMed ID: 21130659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research].
    Holm M; Lehmann F; Laufer S
    Pharm Unserer Zeit; 2008; 37(5):382-92. PubMed ID: 18729263
    [No Abstract]   [Full Text] [Related]  

  • 32. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
    Sisko JT; Tucker TJ; Bilodeau MT; Buser CA; Ciecko PA; Coll KE; Fernandes C; Gibbs JB; Koester TJ; Kohl N; Lynch JJ; Mao X; McLoughlin D; Miller-Stein CM; Rodman LD; Rickert KW; Sepp-Lorenzino L; Shipman JM; Thomas KA; Wong BK; Hartman GD
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1146-50. PubMed ID: 16368234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor tyrosine kinase inhibitor profiling using bead-based multiplex sandwich immunoassays.
    Pötz O; Schneiderhan-Marra N; Henzler T; Herget T; Joos TO
    Methods Mol Biol; 2012; 795():191-202. PubMed ID: 21960224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.
    Liechti C; Séquin U; Bold G; Furet P; Meyer T; Traxler P
    Eur J Med Chem; 2004 Jan; 39(1):11-26. PubMed ID: 14987830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.
    Liu X; Xie H; Luo C; Tong L; Wang Y; Peng T; Ding J; Jiang H; Li H
    J Med Chem; 2010 Mar; 53(6):2661-5. PubMed ID: 20178321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
    Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
    Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors.
    Lüth A; Löwe W
    Eur J Med Chem; 2008 Jul; 43(7):1478-88. PubMed ID: 17981366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
    J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
    Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.